技術指標
指標
數值
方向
MACD(12,26,9)
-0.045
賣出
RSI(14)
34.637
中性
STOCH(KDJ)(9,3,3)
39.913
買入
ATR(14)
0.128
低波動
CCI(14)
-67.234
中性
Williams %R
72.157
賣出
TRIX(12,20)
-1.435
賣出
StochRSI(14)
100.000
超買
搜尋
Beyondspring Inc
BYSI添加自選
1.170USD
-0.015-1.27%
收盤 07-28 16:00（美東）報價延遲15分鐘
48.11M總市值
虧損本益比TTM
關鍵數據
1.190今開
1.210最高
6.62K成交量
虧損本益比TTM
--本益比動
--股利TTM
0.02%換手率
1.185昨收
1.130最低
4.57K成交額
虧損本益比靜
-1.40市淨率
0.00%股息率 TTM
-30.56%ROA
3.44052週最高
0.22量比
-11.12M淨利潤
41.12M總股本
-0.1885每股盈餘TTM
0.43Beta
-321.46%ROE
1.17552週最低
6.74%振幅
100.00%毛利率
48.11M總市值
-5.63回報/風險
5.73%風險率
TradingKey Beyondspring Inc股票評分
單位: USD 更新時間: 2026-07-28操作建議
Beyondspring Inc當前公司基本面數據相對非常健康，增長潛力很大。當前估值合理，在生物技術與醫療研究行業排名185/385位。機構持股佔比非常高，中期看，股價處於下降通道。近一個月，市場表現非常差，但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Beyondspring Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
看好
Beyondspring Inc亮點
亮點風險
BeyondSpring Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. It also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.
分析師目標
基於
0
分析師
--
評級
--
目標均價
--
漲幅空間
Beyondspring Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
技術指標
移動平均線
指標
數值
方向
MA5
1.137
買入
MA10
1.201
賣出
MA20
1.410
賣出
MA50
1.533
賣出
MA100
1.573
賣出
MA200
1.665
賣出
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Beyondspring Inc簡介
BeyondSpring Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. It also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.
公司代碼BYSI
公司Beyondspring Inc
CEOHuang (Lan)
網址https://www.beyondspringpharma.com/en/
公司股東
相關品種
-0.75%
-0.41%
+0.49%
+0.16%
-1.07%
-0.64%
-1.34%
+1.26%
-1.15%
-0.30%
-0.72%
-1.36%
-0.03%
-0.94%
-1.44%
0.00%
+0.24%
+1.34%
+1.29%
-1.45%熱門品種
51750.200
+192.200 (+0.37%)
27319.600
+205.800 (+0.76%)
7341.100
+38.300 (+0.52%)
14698.000
+12.000 (+0.08%)
61425.000
+496.000 (+0.81%)
6239.000
+18.500 (+0.30%)
83.660
-0.281 (-0.34%)
338.360
-1.720 (-0.51%)
190.240
-6.770 (-3.44%)
4090.330
+23.190 (+0.57%)
常見問題
Beyondspring Inc(BYSI)的當前股價是多少？
Beyondspring Inc(BYSI)的當前股價是 1.17。
Beyondspring Inc 的股票代碼是什麼？
Beyondspring Inc的股票代碼是BYSI。
Beyondspring Inc股票的52週最高點是多少？
Beyondspring Inc股票的52週最高點是3.44。
Beyondspring Inc股票的52週最低點是多少？
Beyondspring Inc股票的52週最低點是1.18。
Beyondspring Inc的市值是多少？
Beyondspring Inc的市值是48.73M。
Beyondspring Inc(BYSI)股票的每股收益（EPS TTM）是多少
Beyondspring Inc(BYSI)股票的每股收益（EPS TTM）是-0.02。